Intelligence · Patent portfolio
Regeneron Ireland Designated Patents
Full USPTO pharma patent portfolio for Regeneron Ireland Designated — grant dates, expiration, and drug cross-links.
- Patents
- 8,292
- Expiring ≤24m
- 426
Quick answer
Regeneron Ireland Designated has 8,292 pharmaceutical patents in our USPTO PatentsView index (A61K/A61P). 426 expire within 24 months — use filters for patent-cliff planning.
-
US 11672789
Radiation mitigator and method of use thereof
granted -
US 11673867
Sulfonamide derivative or pharmaceutically acceptable acid-addition salt
granted -
US 11666528
Drug implants containing enzalutamide and methods of use thereof
granted -
US 11667903
Tracking and manipulating cellular RNA via nuclear delivery of CRISPR/CAS9
granted -
US 11666666
Methods and compositions for modifying a mutant dystrophin gene in a cell's genome
granted -
US 11667920
Methods for treating brain injury
granted -
US 11667612
Compositions and methods for delivering pharmaceutical agents
granted -
US 11666609
Methods of treating dog urinary tract infections
granted -
US 11666634
Methods and compositions for management of gastrointestinal disorders
granted -
US 11666660
Glycan-dependent immunotherapeutic molecules
granted -
US 11666661
Methods and compounds for targeted autophagy
granted -
US 11667900
Compositions and methods for enhancing macrophage-mediated antibody guided cancer cell or tumor eradication
granted -
US 11666645
CD200 inhibitors and methods of use thereof
granted -
US 11667784
Copolymers including cinchona alkaloid components and one or more acrylamide or acrylate containing components, complexes containing the same, and methods of using the
granted -
US 11661606
Mature plant transfection using carbon nanotubes
granted -
US 11661599
CRISPR-Cas based system for targeting single-stranded sequences
granted -
US 11660325
Compositions and methods of targeting cancer stem cells
granted -
US 11661411
Quinoxaline compounds and uses thereof
granted -
US 11660571
Microscale device and method for purification of radiopharmaceuticals
granted -
US 11660352
Dual function antibodies specific to glycosylated PD-L1 and methods of use thereof
granted -
US 11661601
Methods for modulating FMR1 expression
granted -
US 11654097
Peptide having activities of skin whitening and uses thereof
granted -
US 11654293
Laser assisted wound healing protocol and system
granted -
US 11655307
Anti-doublecortin-like kinase 1 antibodies and methods of use
granted -
US 11655288
Antibodies to oxidized phospholipids
granted -
US 11654193
Cancer treatment combinations
granted -
US 11649237
Substituted imidazo[1,5-a]pyrazines for IRE1 inhibition
granted -
US 11648297
Bioresponsive particles
granted -
US 11648209
Compositions and methods for organ specific delivery of nucleic acids
granted -
US 11648237
5HT agonists for treating disorders
granted -
US 11648210
Compositions and methods for organ specific delivery of nucleic acids
granted -
US 11648307
Anti-DC-HIL antibodies for cancer diagnosis, prognosis and therapy
granted -
US 11648272
Human kynureninase enzymes and uses thereof
granted -
US 11642849
In vivo live 3D printing of regenerative bone healing scaffolds for rapid fracture healing
granted -
US 11643388
Inhibitors of alpha 2 beta 1 integrin and methods of use thereof
granted -
US 11642401
Activation of resident memory T cells for cancer immunotherapy
granted -
US 11642319
Targeted nanogels for urinary bladder therapies
granted -
US 11642410
Targeting microbubbles
granted -
US 11642419
Compositions and methods for treating cardiovascular related disorders
granted -
US 11643640
Rift valley fever vaccine
granted -
US 11643438
Antimicrobial peptides and methods of use
granted -
US 11642335
Chemical synthesis of clopidogrel active metabolites and disulfide conjugate prodrugs
granted -
US 11642023
Hyperspectral imaging for detection of transmissible spongiform encephalopathy
granted -
US 11642379
Hematopoietic stem cell engraftment
granted -
US 11642354
Methods and compositions comprising ursolic acid and/or resveratrol for treating diabetes, or cancer
granted -
US 11634730
Methods and compositions for RNA-directed target DNA modification and for RNA-directed modulation of transcription
granted -
US 11634683
Non-enzymatic method and milling device
granted -
US 11634691
Compositions and methods of treatment
granted
Frequently asked questions
How many patents does Regeneron Ireland Designated have?
8,292 published patents match the current filter (all indexed). The full portfolio is indexed from USPTO PatentsView (A61K/A61P).
When do Regeneron Ireland Designated patents expire?
426 patents in the full portfolio expire within 24 months. Use the expiring filters above or open individual patent pages for grant and expiration dates.
Where does this data come from?
USPTO PatentsView bulk data filtered to pharmaceutical CPC classes (A61K, A61P), cross-linked to NovaPharmaNews company and drug profiles. See our data sources page for methodology.
Data attribution: Data sources · Patent directory